Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Saline Solution 6Dexmedetomidine 5Sodium Chloride 4Temozolomide 3Sevoflurane 3Propofol 3Methotrexate 3Levetiracetam 3trametinib 2perampanel 2dabrafenib 2Sugammadex 2Neuroimaging 2Methylphenidate 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gentamicins 2Fluorescein 2Anesthesia, Inhalation 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pembrolizumab 1pegvisomant 1olutasidenib 1naxitamab 1lorlatinib 1gadoterate meglumine 1gadobenic acid 1durvalumab 1dexketoprofen trometamol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Cytochrome P-450 CYP2B6 × CNS × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡